Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 1000+

1. Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology International Journal of Dermatology Venereology and Leprosy Sciences · 2024
2. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients International Journal of Trichology · 2018 · 24 citations
3. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial Journal of the American Academy of Dermatology · 2025 · 2 citations
4. Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation Journal of Translational Autoimmunity · 2026
5. 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata 2019
6. Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children Medical alphabet · 2025
7. Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model Journal of Investigative Dermatology · 2026
8. The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article Saudi Medical Horizons Journal · 2026
9. Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis JMIR Dermatology · 2026
10. JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment Mendeley Data · 2025

Community

— no results